Is Midi Health profitable in 2026?

No. Midi Health was not yet profitable as of October 2025, with growth prioritized over near-term earnings, according to a 2026-04-02 outlook summary. The company had just closed a $100M Series D in February 2026, pushing its valuation past $1 billion while still operating at a loss.

Could AI replace Midi Health's doctors?

No. AI cannot legally prescribe hormone therapy, hold clinical liability, or bill insurance payers. Midi uses AI only as an efficiency tool, partnering with Ambience Healthcare since January 2024 for ambient documentation that reportedly saves clinicians over 3 hours per day and tripled clinician network capacity.

Who is Midi Health's biggest competitor?

Midi competes directly with funded menopause telehealth peers Alloy, Evernow, Elektra Health, Gennev, Winona, and Pandia Health, plus larger consumer telehealth players. Hims & Hers launched a menopause and perimenopause specialty on 2025-10-14, aiming for $1B of Hers revenue in 2026, a direct threat to Midi's core market.

How much funding has Midi Health raised?

Midi has raised roughly $250M+ cumulatively as of its February 2026 Series D, which alone brought in $100M led by Goodwater Capital with Foresite Capital and Serena Ventures, pushing the company's valuation past $1 billion, per a 2026-02-03 Fierce Healthcare report.

How many patients does Midi Health serve?

Midi reported treating more than 230,000 patients total and seeing over 25,000 patients weekly as of February 2026, according to a Dealbreaker report dated 2026-02-08. The company also claims insurance-covered access reaching more than 45 million women nationwide.

Does Midi Health face FDA risk over GLP-1 or hormone marketing?

Midi entered weight-loss and GLP-1 prescribing by February 2026 amid a broader FDA enforcement wave targeting telehealth GLP-1 marketing and unsubstantiated claims that began in September 2025 and continued into mid-2026. No Midi-specific FDA or FTC action had been identified as of the latest reporting.

United States · United States

Midi

Telehealth clinic that prescribes HRT and other care for women in menopause, billed through insurance.

Protection under test

Assessed 29 July 2026 · Evidence as of 29 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 29 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Series E fundraising outcome and any Hims & Hers or Ro menopause vertical launch

The call

Midi's licensing and insurance ties keep AI and giant telehealth players out for now, but it competes hard against other licensed menopause clinics for the same patients.

Midi prescribes hormone replacement therapy and other menopause treatments online, which requires a medical license and insurance connections that pure AI companies and unlicensed startups cannot replicate. However, competitors like Hims, Ro, and other licensed telehealth platforms can (and may soon) offer the same services, so Midi's legal shield protects the whole category rather than just Midi itself. The bigger risk is that Midi is expanding into lower-margin product lines like weight-loss drugs and supplements, which could dilute focus and spending away from its core menopause business where it actually holds an advantage.

Why

AI pressure: None apparent. AI chatbots can't hold a prescribing license or bill payers, so Midi uses AI internally for scribing, not as a patient-facing threat. Could AI do the core job? Unlikely.

Bigger players: Hims & Hers or Ro. Both run big telehealth platforms and could add a menopause vertical, but neither has shipped one yet. Could a giant copy it? Probably.

What protects it. Licensed clinicians plus live insurance-billing integrations that block AI-only or unlicensed entrants from prescribing HRT.

What would change this call

Hims & Hers or Ro announces a menopause or HRT vertical within 12-18 months. Would show a capable incumbent entering Midi's defended insurance-based niche.
Midi's revenue mix shifts toward GLP-1 and supplements in future disclosures or press. Would show dilution of the regulatory moat into commodity, less-defensible categories.
FDA or FTC issues an enforcement action on GLP-1 or hormone therapy marketing in 2026-2027. Would show regulatory risk materializing in Midi's core or adjacent business lines.

Key numbers

$100M Series D closed at $1B+ valuation (2026-02-03)
230,000+ patients treated, 25,000 seen weekly (2026-02-08)
Insurance access claimed for 45M women nationwide (2026-02-02)

Named risks

Unprofitable as of October 2025 while rapidly expanding into GLP-1 and supplements. Severity: high
Core revenue figures are unaudited third-party estimates, not company-confirmed. Severity: high
FDA enforcement wave on GLP-1 telehealth marketing active since September 2025. Severity: medium
40+ BBB complaints over insurance billing confusion reported May 2026. Severity: medium
Hims & Hers and other consumer telehealth giants entering menopause vertical directly. Severity: high

Rivals, as read in July 2026

Rival	Direction	Evidence
Hims & Hers	contesting	Launched menopause and perimenopause specialty on 2025-10-14 targeting $1B of Hers revenue in 2026
Alloy Women's Health	contesting	Direct menopause telehealth peer competing for same insurance-covered patient base as of 2026
Evernow	contesting	Funded menopause telehealth rival named repeatedly in 2026 comparison content
Maven Clinic	contesting	Larger women's health benefits unicorn, B2B model contrasted with Midi's consumer-direct pivot, Feb 2026
Elektra Health	contesting	Named menopause telehealth competitor in 2026-05 alternatives comparisons

Questions people ask

Is Midi Health profitable in 2026?: No. Midi Health was not yet profitable as of October 2025, with growth prioritized over near-term earnings, according to a 2026-04-02 outlook summary. The company had just closed a $100M Series D in February 2026, pushing its valuation past $1 billion while still operating at a loss.
Could AI replace Midi Health's doctors?: No. AI cannot legally prescribe hormone therapy, hold clinical liability, or bill insurance payers. Midi uses AI only as an efficiency tool, partnering with Ambience Healthcare since January 2024 for ambient documentation that reportedly saves clinicians over 3 hours per day and tripled clinician network capacity.
Who is Midi Health's biggest competitor?: Midi competes directly with funded menopause telehealth peers Alloy, Evernow, Elektra Health, Gennev, Winona, and Pandia Health, plus larger consumer telehealth players. Hims & Hers launched a menopause and perimenopause specialty on 2025-10-14, aiming for $1B of Hers revenue in 2026, a direct threat to Midi's core market.
How much funding has Midi Health raised?: Midi has raised roughly $250M+ cumulatively as of its February 2026 Series D, which alone brought in $100M led by Goodwater Capital with Foresite Capital and Serena Ventures, pushing the company's valuation past $1 billion, per a 2026-02-03 Fierce Healthcare report.
How many patients does Midi Health serve?: Midi reported treating more than 230,000 patients total and seeing over 25,000 patients weekly as of February 2026, according to a Dealbreaker report dated 2026-02-08. The company also claims insurance-covered access reaching more than 45 million women nationwide.
Does Midi Health face FDA risk over GLP-1 or hormone marketing?: Midi entered weight-loss and GLP-1 prescribing by February 2026 amid a broader FDA enforcement wave targeting telehealth GLP-1 marketing and unsubstantiated claims that began in September 2025 and continued into mid-2026. No Midi-specific FDA or FTC action had been identified as of the latest reporting.

Timeline

2026-07-20Crustdata reports 751 employees, up 54% year over year
2026-05-25BBB reportedly shows 40+ complaints, mostly insurance billing confusion
2026-02-05CEO tells Fortune Midi aims to become a broad consumer health brand
2026-02-03Midi closes $100M Series D led by Goodwater Capital, hits $1B valuation
2026-02-03Midi names new CFO Jason Wheeler, CMO Melissa Waters, CCO Matt Cook
2025-10-14Hims & Hers launches menopause and perimenopause specialty under Hers brand
2025-10-02Midi closes $50M Series C led by Advance Venture Partners
2025-09-01FDA enforcement wave on telehealth GLP-1 marketing begins
2025-05-01Midi launches AgeWell longevity program for women 30 and over
2024-04-24Midi closes $60M Series B led by Emerson Collective with celebrity SPV

Revision history

29 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Ford Motor Whirlpool Solventum